Jennifer Laningham
Family · Conroe, TXNPI 1982013470
Payments from drug & device makers
Across 108 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$322
- Novo Nordisk$219
- Astellas Pharma US Inc$205
- Dexcom, Inc.$156
- Amgen$142
- GSK$127
- plus $950 from 23 others
What the payments were for
- Food & beverage$2,02095%
- Education$995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $322 |
| Novo Nordisk | 14 | $219 |
| Astellas Pharma US Inc | 5 | $205 |
| Dexcom, Inc. | 9 | $156 |
| Amgen | 8 | $142 |
| GSK | 7 | $127 |
| AstraZeneca | 7 | $119 |
| Abbott | 4 | $102 |
| Pfizer | 5 | $99 |
| Inspire Medical Systems, Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Lilly USA, LLC | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Eisai Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Corcept Therapeutics | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $20 |
| Medtronic | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Indivior Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
How this compares
$2,119 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $35,592 |
| Gabapentin | 67 | $1,130 |
| Levothyroxine Sodium | 64 | $811 |
| SynthroidLevothyroxine Sodium | 20 | $617 |
| Pantoprazole Sodium | 36 | $582 |
| Atorvastatin Calcium | 58 | $529 |
| Ropinirole Hcl | 31 | $446 |
| ClopidogrelClopidogrel Bisulfate | 13 | $413 |
| Mupirocin | 24 | $400 |
| Montelukast Sodium | 26 | $387 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $383 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $372 |
| Ezetimibe | 11 | $329 |
| Losartan Potassium | 23 | $329 |
| Escitalopram Oxalate | 14 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $219 | $35,59236 claims |
| AbbVieSynthroid | $322 | $61720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Conroe
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.